Key result
Cardiomyocyte-specific deletion of STAT3 in mice induced cardiac fibrosis, hypertrophy, and impaired diastolic function with preserved ejection fraction, mimicking clinical characteristics of HFpEF.
Why the study?
Treatment options for HFpEF remain limited, and a new animal model is urgently needed for in-depth research.
Does cardiomyocyte-specific deletion of STAT3 induce features of heart failure with preserved ejection fraction in mice?
Does cardiomyocyte-specific deletion of STAT3 induce features of heart failure with preserved ejection fraction in mice?
Cardiomyocyte-specific deletion of STAT3 provides a novel murine model of HFpEF that mimics clinical characteristics of increased cardiac passive stiffness and reduced PKG levels.
Does not change HFpEF care; leaves open whether STAT3 targeting alters diastolic dysfunction in patients.
Aims: There is a high incidence of heart failure with preserved ejection fraction (HFpEF), but the options of treatment are limited. A new animal model of HFpEF is urgently needed for in-depth research on HFpEF. Signal transducer and activator of transcription 3 (STAT3) may affect the passive stiffness of myocardium, which determines cardiac diastolic function. We hypothesized that cardiomyocyte-specific deletion of STAT3 increases cardiac passive stiffness, which results the murine features of HFpEF. Methods and Results: Cardiomyocyte-specific deletion of STAT3 (STAT3cKO) mice was generated by the Cre/FLOXp method. The STAT3cKO mice showed heavier cardiac fibrosis and cardiac hypertrophy comparing with wild-type (WT) mice. Furthermore, STAT3cKO mice showed increased serum brain natriuretic peptide (BNP) level, and growth stimulation expressed gene 2 (ST2) level. Other indicators reflecting cardiac passive stiffness and diastolic function, including end diastolic pressure volume relation, MV A value, MV E value, E/A and E/E' had different fold changes. All these changes were accompanied by decreasing levels of protein kinase G (PKG). Bioinformatic analysis of STAT3cKO mice hearts suggested cGMP-PKG signaling pathway might participate in the pathogenesis of HFpEF by means of adjusting different biological functions. Conclusions: Cardiomyocyte-specific deletion of STAT3 results in a murine HFpEF model which imitates the clinical characteristics partly by affecting cardiac PKG levels. Better understanding of the factors influencing HFpEF may finally provided innovative therapies.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2020) studied Heart Failure with Preserved Ejection Fraction (HFpEF). Cardiomyocyte-specific deletion of STAT3 (STAT3cKO) vs. Wild-type (WT) mice was evaluated on Cardiac diastolic function and passive stiffness. Cardiomyocyte-specific deletion of STAT3 in mice induced cardiac fibrosis, hypertrophy, and impaired diastolic function with preserved ejection fraction, mimicking clinical characteristics of HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: